NEW YORK (GenomeWeb News) — Nanotechnology shop Lumera has spun out a company that will compete in the proteomics tools market, Lumera said yesterday.
 
The company, Plexera Bioscience, has become a wholly owned subsidiary of Lumera and will serve as the operations unit of Lumera's bioscience business that it started in 2006.
 
Plexera will focus on providing “tools, content, and methods to simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers,” Lumera said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.